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Following a probabilistic rather than a deterministic regimen, the action of these short nucleotide sequences
on speciﬁc genes depends on intracellular concentration,which in turn reﬂects the balance betweenbiosynthesis
and degradation. Recent studies have described the involvement of XRN2, an exoribonuclease, in miRNA degra-
dation and PAPD4, an atypical poly(A) polymerase, in miRNA stability. Herein, we examined the expression of
XRN2 and PAPD4 in developing and adult rat hippocampi. Combining bioinformatics and real-time PCR,we dem-
onstrated that XRN2 and PAPD4 expression is regulated by the uncorrelated action of transcription factors,
resulting in distinct gene expression proﬁles during development. Analyses of nuclei position and nestin labeling
revealed that both proteins progressively accumulated during neuronal differentiation, and that they are weakly
expressed in immature neurons and absent in glial and endothelial cells. Despite the differences in subcellular lo-
calization, both genes were concurrently identiﬁed within identical neuronal subpopulations, including speciﬁc
inhibitory interneurons. Thus, we cope with a singular circumstance in biology: an almost complete intersected
expression of functional-opposed genes, reinforcing that their antagonistically driven actions on miRNAs “make
sense” if simultaneously present at the same cells. Considering that the transcriptome in the nervous system is
ﬁnely tuned to physiological processes, it was remarkable that miRNA stability-related genes were concurrently
identiﬁed in neurons that play essential roles in cognitive functions such as memory and learning. In summary,
this study reveals a possible new mechanism for the control of miRNA expression.
© 2013 Elsevier Inc. All rights reserved.Introduction
MicroRNAs (miRNAs), endogenous single-stranded RNA approxi-
mately 21 nucleotides in length are fundamental post-transcriptional
regulators of gene expression (Ambros and Lee, 2004; Brennecke
et al., 2005; He and Hannon, 2004). Regulation of gene expression by
miRNAs is highly conserved among species, and has been studied in a
wide variety of processes and cell types (Matzke and Matzke, 2004).
In the nervous system, the role ofmiRNAs has also been investigated
in fundamental processes such as development (Decembrini et al.,
2009; Gao, 2008; Li et al., 2011; Sanuki et al., 2011; Somel et al.,
2011), cell differentiation (Andersson et al., 2010; Zheng et al., 2010),
adaptation to ambient demands (Bredy et al., 2011; Konopka et al.,no competing interests exist.
istemas Complexos, Centro de
ral do ABC, Av. Atlântica 420,
ara).
ghts reserved.2011; Krol et al., 2010), neurodegeneration, and other disorders
(Eacker et al., 2009; Harraz et al., 2012; Xu et al., 2013). During hippo-
campal formation, changes in miRNA expression govern synaptic plas-
ticity (Cohen et al., 2011; Lee et al., 2012) such as memory and
learning (Konopka et al., 2011; Wang et al., 2012). Following a probabi-
listic rather than deterministic operandi (Ragan et al., 2011), miRNA
speciﬁcity depends on its cytosolic concentration, which in turn is the
result of the balance between biosynthesis and degradation. While
mechanisms underlying miRNA synthesis have been exhaustively in-
vestigated (Diederichs and Haber, 2007; Koscianska et al., 2011; Wu
et al., 2012), little is known about proteins involved in miRNA stability
and degradation (Bail et al., 2010). Recent studies have described the in-
volvement of XRN2, a 5′→ 3′ exoribonuclease, in miRNA degradation
and PAPD4, an atypical poly(A) polymerase also known as GLD-2, in
miRNA stability (Kai and Pasquinelli, 2010; Katoh et al., 2009).
In this study, we thoroughly examined the ontogenesis of XRN2 and
PAPD4 in hippocampal neurons, progenitor, glial, and endothelial cells
using a combination of different methods and analyses. Studies
employing hippocampal formation include several advantages such as
a constant cell proliferation state, synaptic plasticity, and neuronal di-
versity in well-characterized neuronal circuits. We demonstrate that
Table 1
Primary antibodies used in immunohistochemistry (IHC) and Western blot (WB)
experiments.
Antibody Dilution Manufacturer Catalog number
Rabbit anti-XRN2 1:200 (IHC)
1:1000 (WB)
Abcam ab72181
Rabbit anti-PAPD4 1:200 (IHC)
1:1000 (WB)
Abcam Ab103884
Mouse anti-nestin 1:200 (IHC) Millipore MAB353
Mouse anti-GFAP 1:200 (IHC) Sigma-Aldrich G3893
Mouse anti-eNOS 1:200 (IHC) BD Biosciences 610297
Mouse anti-calretinin 1:500 (IHC) Millipore MAB1568
Mouse anti-parvalbumin 1:500 (IHC) Sigma-Aldrich P3088
Mouse anti-beta actin 1:20,000 (WB) Sigma-Aldrich A5316
547E.R. Kinjo et al. / Experimental Neurology 248 (2013) 546–558genes with antagonist driven-actions on miRNAs may represent an
additional mechanism in the control of the transcriptome.
Material and methods
Ethics statement
Experiments with animals were conducted in accordance with
guidelines of the National Institute of Health and the Brazilian Society
for Laboratory Animals. The experimental protocol was approved by
the Ethics Committee in Animal Experimentation of the Institute of
Biomedical Sciences/University of São Paulo (ICB/USP).
Animal procedures
Experiments were carried out with Long Evan rats (Rattus norvegicus)
kept on a 12 h light/dark cycle with lights on at 06:00 a.m. Embryonic
day 21 (E21) and postnatal day 5 (P5), P10 and P60 rats were eutha-
nized with an overdose of ketamine (30 mg/100 g of body weight,
i.m., Parke-Davis, Ann Arbor, MI, USA) and xylazine (2 mg/100 g, i.m.,
West Haven, CT, USA) between 10:00 and 12:00 a.m. Following eutha-
nasia, their hippocampi were dissected for different methodologies.
Transcription factor binding site analysis
Transcription factor binding sites (TFBS) were analyzed using Map-
per2 software (Marinescu et al., 2005). After identifying putative tran-
scription factors, they were categorized on the basis of the score and
E-value parameters. The score is the logarithm to the base 2 of the
ratio P(seq|HMM)/P(seq|null), where P(seq|HMM) is the probability of
the target sequence according to the HMM model and P(seq|null) is
the probability of the sequence according to a null model distribution.
Therefore, the greater the score, the better is the match between the
hit and the model. In contrast, the E-value is based on the number of
sequences queried in the database and is a measure of the expected
number of false positives that will have scores equal to or greater than
the score of the hit. The smaller the E-value, the more signiﬁcant is the
hit.
RNA isolation, cDNA synthesis and real-time PCR
The HIPPOCAMPI were directly homogenized in 1–1.5 ml of a TRIzol
reagent (Invitrogen, Carlsbad, CA, USA) and total RNAwas extracted fol-
lowing themanufacturer protocol and previously described procedures
(Kihara et al., 2005; Paschon et al., 2012). Brieﬂy, following two chloro-
form extraction steps, RNA was precipitated with isopropanol and
the pellet washed twice in 70% ethanol. After air-drying, RNA was
resuspended in DEPC-treatedwater and the concentration of each sam-
ple obtained from A260 measurements. Residual DNA was removed
using DNase I (Amersham, Piscataway, NJ, USA) following themanufac-
turer protocol. Quantitative analysis of gene expression was carried out
with a Rotor-Gene 6000 real-time rotary analyzer (Corbett Robotics
Inc., San Francisco, CA, USA) with speciﬁc primers for rat XRN2 (for-
ward, 5′-TCGAGGAGGGCGACAGGGAT-3′; reverse, 5′-GGGCGGTGGCA
AAGGGTACT-3′) and rat PAPD4 (forward, 5′-ACAGGGTTGTCTACGCCG
CC-3′; reverse, 5′-CGCGGGCGTGTTAAGTTGGG-3′). cDNA abundance
for cyclophilin A (forward, 5′-GCGTTTTGGGTCCAGGAATGGC-3′; re-
verse, 5′-TTGCGAGCAGATGGGGTGGG-3′) was determined as an inter-
nal control. For each 20 μl reverse transcription reaction, 4 μg of total
RNAwasmixedwith 1 μl of oligo-dT primer (0.5 μg; Invitrogen) and in-
cubated for 10 min at 65 °C. After cooling on ice the solutionwasmixed
with 4 μl of 5× ﬁrst strand buffer, 2 μl of 0.1 M DTT, 1 μl of dATP, dTTP,
dCTP and dGTP (each 10 mM), and 1 μl of SuperScript III reverse tran-
scriptase (200 U; Invitrogen) and incubated for 60 min at 50 °C. Reac-
tion was inactivated by heating at 70 °C for 15 min. All PCR assays
were performed as follows: after initial activation at 50 °C for 2 minand 95 °C for 10 min, cycling conditions were 95 °C, 10 s and 60 °C,
1 min. Dissociation curves of PCR products were obtained by heating
samples from 60 to 95 °C, in order to evaluate primer speciﬁcity.
PCR statistical analysis
Relative quantiﬁcation of target gene expression was evaluated
using the comparative CT method as previously described in detail
(Kihara et al., 2008b; Medhurst et al., 2000). In the present study, we
considered P60 animals as the control group. Values were entered into
one-way analysis of variance (ANOVA), followed by pairwise compari-
sons in Tukey's HSD test, with the signiﬁcance level set at 5%.
Western blotting
The hippocampi were rapidly dissected, washed with phosphate
buffered saline (PBS), and homogenized in a RIPA buffer (50 mM Tris,
150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100,
and protease inhibitors). Homogenates were centrifuged for 20 min at
14,000 g and 4 °C to remove insoluble material. Protein concentration
was determined using the BCA method (Thermo Scientiﬁc, Rockford,
IL, USA, catalog # 23225), and bovine serum albumin was used as the
standard as per the manufacturer's instructions. Proteins in the mem-
brane preparations were separated using sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE; 10% gel) and trans-
ferred onto nitrocellulose membranes (Santos-Bredariol et al., 2006).
Blots were incubated with 5% non-fat milk in a TBST buffer for 2 h at
room temperature to block nonspeciﬁc binding of antibodies. After rins-
ing the blots with TBST, they were incubated overnight with primary
antibodies against XRN2, PAPD4, and beta-actin diluted in TBST/3%
non-fat milk (Table 1). After incubation with primary antibodies, blots
were rinsed with TBST and incubated with goat anti-rabbit peroxidase
(ECL™ kit; Amersham, Buckinghamshire, England) for 2 h at room tem-
perature. Detection of labeled proteins was achieved by using the en-
hanced chemiluminescent system (ECL™ kit; Amersham). The optical
band densities (OBDs)were determined using ImageJ software (Nation-
al Institute ofMental Health, Bethesda,Maryland, USA). OBDswere nor-
malized against protein levels expressed in the adult hippocampus. Data
from four independent experiments were analyzed using one-way
ANOVA with repeated measures, followed by pairwise comparisons
with Tukey's HSD test.
Immunohistochemistry
Brains were collected and ﬁxed for 8 h in 1% paraformaldehyde
(PFA) in phosphate buffered saline (PBS; 0.1 M, pH 7.3), and cryo-
protected in a 30% sucrose solution for at least 48 h at 4 °C. After em-
bedding the brain in an Optimum Cutting Temperature compound
(OCT, Sakura Finetek USA, Inc., Torrance, CA, USA), coronal sections
(12 μm)were obtained on a Leica CM1850 cryostat (LeicaMicrosystems
Fig. 1.Analysis of XRN2 and PAPD4 transcription factor binding sites and quantiﬁcation of gene expression during hippocampal development. (A) Representation and localization of XRN2
and PAPD4 genes. Analysis of transcription binding sites (TFBS) located as far as 2000 bp upstream identiﬁed 24 different transcription factors that may regulate both XRN2 and PAPD4.
(B, C) Transcription factors were plotted according to score and E-value parameters in a scattergram. (D) Pearson's correlation analyses revealed coefﬁcient values extremely close to zero
for both parameters. (E) Ampliﬁcation plots of hippocampal samples obtained from 21-day-old embryos (E21, red) and adult rats (P60, green) using primers designed for XRN2. E21
samples required fewer cycles for visualization of the ampliﬁcation plot compared with P60 samples. (F) Dissociation curves of the ﬁrst derivative plot from normalized ﬂuorescence
of amplicons generated by XRN2 primers against temperature. The melting temperature (Tm) of PCR products (indicated by the peak of the solid line) exactly matched the theoretical
Tm expected for the amplicon. (G, H) Ampliﬁcation plots and dissociation curves from E21 (red) and P60 (green) cDNA samples using PAPD4 primers. E21 and P60 samples have similar
ampliﬁcation plots. (I) XRN2 expression during hippocampal development normalized to the control at P60. We observed higher expression levels at E21, P5, and P10 than those at P60.
(J) PAPD4 expression during hippocampal development normalized by P60.We observed higher transcript levels at P5 than those at P60. Cyclophilin A expressionwas used as an internal
control. Bars represent standard errors of the mean. *P b 0.05, **P b 0.01, ***P b 0.001 vs. P60 in Tukey's HSD pairwise comparisons after one-way ANOVA.
548 E.R. Kinjo et al. / Experimental Neurology 248 (2013) 546–558Inc., IL, USA). Brain sections containing the hippocampus were incubat-
ed overnight with primary antibodies in a solution containing 5%
normal goat serum and 0.3% Triton X-100 in PBS at room temperature.
All the antibodies and speciﬁc concentrations used in this study are
listed in Table 1. After several washes, brain sections were incubatedFig. 2. Detection and quantiﬁcation of XRN2 and PAPD4 protein levels during hippocampal de
Beta-actin (42 kDa) was used as an internal control. Optical band densities (OBD) at E21
experiments (n = 4). (B) We observed that XRN2 protein levels decreased at E21, P5, and P1
at E21, P5, and P10 than those at P60. *P b 0.001, **P b 0.01 vs. P60 in Tukey's HSD pairwisewith a goat antiserum against rabbit IgG tagged to Alexa 488 (1:200–
1:500, Invitrogen) diluted in 0.3% Triton X-100 in PBS for 2 h at room
temperature. For double-labeling experiments, we employed secondary
antibodies conjugated to Alexa 546 and Alexa 647 (1:200–1:500,
Invitrogen). Controls for the experiments consisted of the omission ofvelopment. (A)Western blots of XRN2 and PAPD4 in developing and adult hippocampi.
, P5, and P10 were normalized against the OBD at P60 (adult) in three independent
0 compared with those at P60. (C) In contrast, we observed lower PAPD4 protein levels
comparisons after one-way ANOVA.
Fig. 3.XRN2 immunolabeling indeveloping and adult rat hippocampi. XRN2 (green) immunolabeling in coronal sections of developing and adult hippocampi followed by counter-staining
with 4′,6-diamidino-2-phenylindole (DAPI, blue). (A–H) XRN2 immunoreactivity in the CA1 regionwas observed in pyramidal cell nuclei and in some cells within strata oriens, radiatum,
and lacunosum-moleculare in developing and adult hippocampi. (I–P) In the CA3 region of the hippocampus in all studied ages, XRN2 labeling was also observed in pyramidal cell nuclei
and in strata oriens, radiatum, and lacunosum-moleculare. In the dentate gyrus, XRN2 immunolabeling at E21 (Q, U) was detected in cells located predominantly in the hilus, with
extremely sparse staining in the granule cell layer. At P5 (R, V), XRN2 labelingwas clearly detected in the granule cell layer. At P10 (S, T) and P60 (W,X), XRN2-positive cellswere observed
both in the hilus and granule cell layer. Scale bar: 50 μm.
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staining of brain sections was achieved using 4′,6-diamidino-2-
phenylindole (DAPI). After washing, the specimen was mounted using
Vecta Shield (Vector Labs, Burlingame, CA, USA), and analyzed with a
Nikon TS100F inverted microscope (Nikon Instruments Inc., Melville,
NY, USA). Figuresweremountedwith Adobe Photoshop CS5.Manipula-
tion of the imageswas restricted to brightness and contrast adjustments
of the whole image.
Image quantiﬁcation
Image analysis was performedwith ImageJ software (National Insti-
tute of Mental Health, Bethesda, Maryland, USA) and NIS-elements AR3.2 64-bit software (Nikon Instruments Inc.), as previously described
(Kihara et al., 2008a). After channel separation (RGB) of the color im-
ages, we performed quantiﬁcation of the mean pixel intensity, where
values correspond to the brightness of the pixels of delimited areas cor-
responding to the cell nuclei. Each value was normalized by the mean
pixel intensity of all labeled cells in the same image. In some cases,
areas of interest (AOIs) were deﬁned by the labeling in one channel,
and analysis was performed in another channel, as for instance,
labeling of XRN2 and PAPD4 in the green channel, deﬁned by DAPI la-
beling in the blue channel. Pearson's correlation between PAPD4 and
DAPI was performed employing 6–8 hippocampal slices of 3 animals
at ages E21 and P60. The coefﬁcients provided by each analysis were
used to calculate the mean of Pearson's correlation in E21 and P60
Fig. 4. PAPD4 immunolabeling in the developing and adult rat hippocampi. PAPD4 (green) immunolabeling of the developing and adult rat hippocampi, counter-stainedwith DAPI (blue).
PAPD4 immunostaining in the CA1 region of the hippocampus at E21 (A, E) was observed primarily in the cytosol of pyramidal cells, and also in strata oriens, radiatum, and lacunosum-
moleculare. At P5 (B, F) and P10 (C, G), PAPD4 progressively accumulates in nuclei, whereas at P60 (D, H), a clear nuclear labeling in pyramidal cells was observed in addition to a few
positive cells in strata oriens, radiatum, and lacunosum-moleculare. (I–P) In the CA3 region, we observed similar changes in PAPD4 subcellular distribution during development i.e., a pro-
gressive accumulation of the protein in cell nuclei. In the dentate gyrus (DG), PAPD4 labeling at E21 (Q, U)was primarily seen in the cytosol of cells located in the hilus, withweak staining
in the granule cell layer. At P5 (R, V) and P10 (S, W), an increase in PAPD4 in the granule cell layer was detected, and in hilar cells, we observed a progressive accumulation of PAPD4 in
nuclei. (T, X) In the DG at P60, PAPD4 immunoreactivity was observed in cells located within the granule cell layer and hilus. Scale bar: 50 μm.
550 E.R. Kinjo et al. / Experimental Neurology 248 (2013) 546–558hippocampi. Values were exported to Excel (Microsoft, Redmond, WA,
USA) or Statistica (StatSoft, Tulsa, OK, USA) for the appropriate statisti-
cal analysis. Images and charts were prepared with Adobe Photoshop
CS5 (Adobe Systems Inc., San Jose, CA, USA).
Results
XRN2 and PAPD4 transcription is speciﬁcally regulated, resulting in distinct
gene expression proﬁles during development
XRN2 and PAPD4 genes are located on distinct chromosomes, and
have different lengths (3787 vs. 1871 bp) but similar open readingframes (1685 and 1454 bp, respectively). Using bioinformatics, we
deﬁned transcription factor binding sites (TFBS) located as far as
2000 bp upstream, which would be under the control of 194 different
transcription factors. From these, we veriﬁed that only 24 transcription
factors may regulate both XRN2 and PAPD4. We plotted these 24 TFBS
according to their score and E-value parameters, which estimate the
probability of a given factor to regulate gene transcription at a speciﬁc
DNA binding site (Marinescu et al., 2005). Pearson's correlation analy-
ses revealed coefﬁcient values extremely close to zero for both param-
eters. Taken together, these results indicated that XRN2 and PAPD4
are most probably not regulated by common transcription factors
(Figs. 1, A–D).
Fig. 5. XRN2 and PAPD4 localization in nestin-positive cells. To verify XRN2 presence (green) in immature neurons, we performed anti-nestin (red) double-labeling experiments on cor-
onal hippocampal sections from 21-day-old embryos (E21) followed by counter-stainingwith DAPI (blue). (A) Nestin stainingwas rarely detected near XRN2-positive nuclei, as observed
in the representative image of the CA1 region of the hippocampus. (B–D) In highmagniﬁcation of the selected area, XRN2 staining was virtually absent in nestin-positive cells (white ar-
rows) compared with bright nuclear labeling observed in nestin-negative cells (white arrowheads). (E) Quantiﬁcation of pixel intensity conﬁrmed that XRN2 levels were signiﬁcantly
lower in nestin-positive than in nestin-negative cells. In addition,we performed double-staining using anti-PAPD4 (green) and anti-nestin (red) on coronal sections of the E21 hippocam-
pus, followedby counter-stainingwithDAPI (blue). (F) Similarly, PAPD4 labelingwas rarely seen nearnestin-positive cells, as shown in the representative image of the CA1 region. (G–I) In
a highmagniﬁcation of the selected area, weak PAPD4 labelingwas observed in nestin-positive cells (red arrows) comparedwith cytoplasmic staining of nestin-negative cells (red arrow-
heads). (J) Quantiﬁcation of pixel intensity conﬁrmed that PAPD4 levels were signiﬁcantly lower in nestin-positive than in nestin-negative cells. Bars represent standard errors of the
mean. *P b 0.001 by t test. Scale bar: 12.5 μm.
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ated ampliﬁcation plots from cDNA serial dilutions. Dissociation curves
of these PCR products were obtained by heating samples from 60 °C to
95 °C. A single peak was observed and found to match the theoretical
melting temperature previously calculated, indicating speciﬁcity of the
primers. Ampliﬁcation plots indicated that XRN2 expressionwas higher
at E21 than at P60, whereas PAPD4 showed no signiﬁcant differences in
transcript levels at both ages (Figs. 1, E–H).
We observed XRN2 and PAPD4 transcripts to have distinct expres-
sion proﬁles and that they are expressed at all developmental ages
investigated in this study. Our results indicated that XRN2 expression
was higher in the hippocampus at E21 (2^1.29 = 2.45-fold-expression,
P b 0.001), P5 (2^1.01 = 2.02-fold-expression, P b 0.001), and P10
(2^0.60 = 1.51-fold-expression, P b 0.01) than at P60. In contrast, our
results indicated that PAPD4 expression peaked at P5 (2^0.53 = 1.44-
fold-expression, P b 0.05), and it remained stable at the other develop-
mental ages studied, similar to P60 (Figs. 1, I–J). In these PCR experi-
ments, cyclophilin expression was used as an internal control (data
not shown).XRN2 and PAPD4 have distinct protein levels during
hippocampal development
Because XRN2 and PAPD4 transcripts were present in the develop-
ing and adult hippocampi, we subsequently examined whether these
genes are actually translated into proteins. We were able to detect
these proteins, and they appeared to be speciﬁcally regulated during
hippocampal development (Fig. 2A). We observed the XRN2 protein
level to match the gene expression proﬁle previously shown. The
XRN2 protein level was higher in the hippocampus at E21 (919%,
P b 0.001), P5 (860%, P b 0.001), and P10 (720%, P b 0.001) than at
P60 (Fig. 2B). In contrast, the PAPD4 protein level was different from
its gene expression proﬁle during hippocampal development. A lower
level of PAPD4 was detected at E21 (53%, P b 0.01), P5 (38%,
P b 0.001), and P10 (51%, P b 0.01) than at P60 (Fig. 2C).XRN2 and PAPD4 share a similar distribution pattern in the developing and
adult hippocampi
Immunohistochemistry was employed to examine the spatial distri-
bution of XRN2 in the developing and adult hippocampi. XRN2 labeling
was predominantly detected in cell nuclei with sporadic cytosolic stain-
ing. At E21, XRN2 labeling in CA1 and CA3 regions was mostly observed
in the pyramidal cell layer and in some cells within the strata oriens,
radiatum, and lacunosum-moleculare. In the dentate gyrus (DG),
XRN2-positive cells were predominantly seen in the hilus, with ex-
tremely sparse labeling in the granule cell layer, which ismostly formed
by immature neurons from E17 to a few weeks after birth (Fig. 3, ﬁrst
column). At P5, the distribution pattern of XRN2 in the CA1 and CA3 re-
gions was maintained. However, we observed labeling in the granule
cell layer of the DG (Fig. 3, second column). At P10 and P60, XRN2
immunolabeling in the CA1 and CA3 regions was similar to that ob-
served in the P5 hippocampus, with nuclear staining of pyramidal
cells and a few XRN2-positive nuclei in the strata oriens, radiatum,
and lacunosum-moleculare. XRN2-positive cells were observed both
in the hilus and granule cell layer of the DG (Fig. 3, third and fourth
columns).
We observed a similar pattern of PAPD4 distribution in the hippo-
campus, although changes in its subcellular localization were observed
duringdevelopment. At E21, PAPD4 labelingwasmainly cytosolicwithin
pyramidal cells and also in the strata oriens, radiatum, and lacunosum-
moleculare within CA1 and CA3 regions (Fig. 4, ﬁrst column). A similar
labeling pattern was observed in the hilus, with weak staining in the
granule cell layer. In the P5 and P10 hippocampi (Fig. 4, second and
third columns) we observed a progressive accumulation of PAPD4 in
the nuclei of cells located within the CA1 and CA3 regions. In the DG,
we detected an obvious increase in PAPD4 in the granule cell layer and
a gradual increase in the nuclei of hilar cells. At P60, we observed nuclear
labeling in pyramidal cells within the CA1 and CA3 regions. A few posi-
tive cells in the strata oriens, radiatum, and lacunosum-moleculare
were also observed. In addition, PAPD4-positive labeling was observed
in the granule cell layer and hilus (Fig. 4, fourth column).
Fig. 6. XRN2 progressively accumulates in pyramidal cell nuclei along themigration route. To analyze XRN2 (green) levels in distinct areas of themigration pathway, we performed dou-
ble-labeling experiments on coronal hippocampal sections at E21, P5, P10, and P60, followed by counter-staining with DAPI (blue). (A) Schematic representation of the developing hip-
pocampus and migration route. Movement of neurons in the CA3 region is composed of two vectors, as represented by dashes and solid red lines. Immature neurons ﬁrst cross the
infrapyramidal area (red) on their way to the suprapyramidal region (blue). (B) During the migration process, XRN2 is progressively accumulated in nuclei of maturating neurons at
P5. Quantiﬁcation of pixel intensity conﬁrmed the level of the green channel to be higher near the suprapyramidal region. (C–E) In a high magniﬁcation of the selected area, moderate
staining was observed in cells located near the infrapyramidal region (white arrows) compared with those in the suprapyramidal region (white arrowheads). (F–H) Quantiﬁcation of
pixel intensity revealed a signiﬁcant difference in XRN2 labeling at E21 and P5. (I) Schematic representation of the adult hippocampus. (J) XRN2 labeling in the adult hippocampus
was uniform throughout the CA3 pyramidal cell layer, as indicated by the intensity pixel proﬁle. (K–M) In a high magniﬁcation of the selected area, XRN2 immunolabeling was uniform
and stable compared with neurons located at the infra (red arrows) vs. supra (red arrowheads) borders of the pyramidal cell layer. (N) We did not detect signiﬁcant differences in pixel
analysis by comparing XRN2 labeling in these areas. Bars represent standard errors of the mean. *P b 0.01 in Tukey's HSD pairwise comparisons after one-way ANOVA. Scale Bar: 25 μm.
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Since XRN2 and PAPD4 were detected in the developing hippocam-
pus, we subsequently examined whether these proteins are also present
in immature neurons. For this purpose, we performed double-labeling
experiments in the E21 hippocampus using nestin, a marker for neural
progenitor cells (Frederiksen andMcKay, 1988). Nestin is an intermediate
ﬁlament protein; therefore, nuclei surrounded by this marker were used
to identify nestin-positive cells and used for the quantiﬁcation of mean
pixel intensity (n = 4). We observed that nestin-positive cells displayed
extremely low levels of XRN2 (Figs. 5, A–E) labeling compared with
nestin-negative cells (0.17 ± 0.04 vs. 1.36 ± 0.09, P b 0.001). Similar re-
sults were observed for PAPD4 (Figs. 5, F–J) in nestin-positive compared
with that in nestin-negative cells (0.3 ± 0.06 vs. 1.43 ± 0.06, P b 0.001).
XRN2 and PAPD4 progressively accumulate in neuronal nuclei
To conﬁrm our results that both XRN2 and PAPD4 accumulate inma-
ture neurons, we assessed the presence of these proteins during neuro-
nal differentiation. We followed the migration route of cells towards
their deﬁnitive location, a phenomenon occurring simultaneously withneuronal differentiation (Fig. 6A). XRN2 expression appeared to increase
during neuronal maturation. We observed this gradual, differential
labeling in the CA3 region at different time points during hippocampal
development (Figs. 6, B–E).
Wequantiﬁed themeanpixel intensity (n = 3) of pyramidal cells lo-
cated near the suprapyramidal region and adjacent to the infrapyramidal
region (Figs. 6, F–H). XRN2 labeling was signiﬁcantly higher in the
suprapyramidal segment of the CA3 pyramidal layer than in the
infrapyramidal segment in E21 (1.2 ± 0.05 vs. 0.66 ± 0.04, P b 0.01)
and P5 (1.3 ± 0.06 vs. 0.67 ± 0.08, P b 0.01) hippocampi. In contrast,
we did not observe signiﬁcant changes at P60 (Figs. 6, I–N).
Based on the changes observed in PAPD4 labeling during hippocam-
pal development i.e., the translocation of this protein from the cytosol to
the nucleus, we aimed to analyze this phenomenon in the E21 and P60
hippocampus (Fig. 7). After combining pixel intensity proﬁles and digi-
tal zooming with RGB decomposition data from E21 (Figs. 7, A–D) and
P60 (Figs. 7, E–H) hippocampi, we observed PAPD4 to transit from the
cytosol to nucleus. Mean values from Pearson's analysis (n = 3) re-
vealed no spatial correlation between DAPI and PAPD4 signals at E21
(−0.008 ± 0.07), indicating a cytosolic distribution of the protein at
this age. Nevertheless, a strong correlation between DAPI and PAPD4
Fig. 7. PAPD4 translocates from the cytoplasm to the nucleus duringmaturation of pyramidal cells. To analyze PAPD4distribution (green) in speciﬁc cellular compartments, we performed
immunolocalization experiments on coronal sections of E21, P5, P10, and P60 hippocampi, followed by counter-staining with DAPI (blue). (A) In the CA1 region of the E21 hippocampus,
we observed PAPD4 immunoreactivity in the cytoplasm. Pixel intensity proﬁles revealed spatial differences in blue and green channels. (B–D) Under high magniﬁcation of the selected
area, PAPD4 failed tomergewith DAPI (white arrows). (E) However, PAPD4 accumulated in neuronal nuclei in the CA1 region of themature hippocampus. Pixel intensity proﬁles revealed
the spatialmatchof green andblue channels. (F–H)Under highmagniﬁcation of the selected area, PAPD4was observed to colocalizewithDAPI. (I, J) Scattergrams represent the correlation
between green and blue channels in E21 and P60 images, with all pixel intensities combinations of both channels. (K) Quantitative analysis of E21 and P60 hippocampi revealed a signif-
icant difference in Pearson's correlation. Bars represent standard errors of the mean. *P b 0.01 by t test. Scale bar: 25 μm.
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dominantly nuclear localization. Statistical signiﬁcance was obtained
(P b 0.01), which revealed that PAPD4 translocates from the cytosol to
the nucleus as development progresses (Figs. 7, I–K).
XRN2 and PAPD4 are virtually absent in glial and endothelial cells
Considering that XRN2 and PAPD4 accumulate along with neuronal
differentiation, we subsequently evaluated whether these proteins are
also expressed in other differentiated cells. Double-labeling experi-
ments using anti-GFAP (Figs. 8 and 9) and anti-eNOS (Fig. 10) were
performed to determine whether these proteins are expressed in glial
and endothelial cells, respectively.
Meanpixel intensity analyses (n = 3) performed at P5 (Figs. 8, A–E)
and P60 (Figs. 8, F–J) revealed XRN2 to be almost nearly absent in GFAP-
positive cells compared with that in GFAP-negative cells, both at P5(0.31 ± 0.05 vs. 1.53 ± 0.08, P b 0.001) and P60 (0.37 ± 0.03 vs.
1.54 ± 0.11, P b 0.001). Similar results were observed for PAPD4 at P5
(Figs. 9, A–E) and P60 (Figs. 9, F–J), in GFAP-positive and GFAP-
negative cells at P5 (0.22 ± 0.004 vs. 1.51 ± 0.03, P b 0.001) and P60
(0.33 ± 0.04 vs. 1.5 ± 0.05, P b 0.001).
In coronal P60 hippocampal sections, eNOS-labeled vessels were ob-
served in all regions analyzed along with endothelial cells with typical
elongated nuclei. Experiments using anti-eNOS (n = 4) revealed that
both XRN2 (Figs. 10, A–D) and PAPD4 (Figs. 10, E–H) do not accumulate
in endothelial cells.
XRN2 and PAPD4 accumulate in calretinin-containing hippocampal
interneurons
After we determined the presence of XRN2 and PAPD4 in differ-
entiated and mature neurons, we subsequently investigated in which
Fig. 8. XRN2 is virtually absent in astrocytes from the developing and adult hippocampi. To verify the presence of XRN2 immunolabeling (green) in astrocytes from the hippocampus, we
performed double-labeling experiments on coronal sections of P5 and P60 hippocampi using anti-glial ﬁbrillary acidic protein (GFAP, red), followed by counter-stainingwith DAPI (blue).
(A) At P5, GFAP-positive cells (white arrows) were weakly immunoreactive for XRN2. (B–D) Under high magniﬁcation of the selected area, we observed faint XRN2 immunolabeling of
glial cell nuclei (blue arrows), as opposed to the bright staining of GFAP-negative cells (blue arrowheads). (E) Quantiﬁcation of pixel intensity revealed a signiﬁcant difference in XRN2
labeling betweenGFAP-positive and -negative cells in the P5 hippocampus. (F) In the P60hippocampus, XRN2 immunolabelingwas virtually absent in glial cell nuclei (white arrowheads).
(G–I) Under highmagniﬁcation of the selected area, we observed XRN2 to weakly accumulate in GFAP-positive cells (red arrow) compared with that in GFAP-negative cells (red arrow-
heads). (J) Quantiﬁcation of pixel intensity revealed a signiﬁcant difference in XRN2 immunolabeling between GFAP-positive and -negative cells in the P60 hippocampus. Bars represent
standard errors of the mean. *P b 0.001 in t test. Scale bar: 25 μm.
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teins were expressed. For this purpose, we performed double-labeling
experiments using anti-calretinin (CR), a calcium binding protein that is
mostly present in interneurons specializing in the control of other
GABAergic interneurons (Gulyas et al., 1996), the so-called interneuron-
speciﬁc interneurons (Chamberland and Topolnik, 2012). We could ob-
serve that CR-positive neurons in CA1, CA3, and DG regions are labeled
with bothXRN2 (Figs. 11, A–E) andPAPD4 (Figs. 11, F–J). After combining
the pixel intensity proﬁles and digital zooming followed by RGB decom-
position data from the CA1 region, we indicated that XRN2 and PAPD4
are present in those cells. Moreover, quantiﬁcation of pixel intensities
(n = 3) revealed the labeling of XRN2 (0.95 ± 0.25 vs. 0.96 ± 0.07)
and PAPD4 (1.08 ± 0.24 vs. 0.84 ± 0.11) to be similar between CR-Fig. 9.PAPD4 is virtually absent in astrocytes from thedeveloping and adult hippocampi. To veri
double-labeling experiments using GFAP (red) on coronal sections of P5 and P60 hippocampi
GFAP-positive cells (white arrows). (B–D) Under high magniﬁcation of the selected area, we o
GFAP-negative cells (blue arrowheads). (E) Quantiﬁcation of pixel intensity revealed the PAPD
P5 hippocampus. (F) Similarly, we did not observe PAPD4 immunolabeling in glial cells from t
area, we observed PAPD4 staining to be virtually absent inmost GFAP-positive cells (red arrow)
of pixel intensity revealed the PAPD4 signal to beweaker in GFAP-positive than in GFAP-negati
t test. Scale bar: 25 μm.positive and -negative cells. In both cases, no signiﬁcant differences
were observed using paired t test.
PAPD4 is highly expressed in interneurons that are speciﬁcally responsible
for regulating the input integration of pyramidal cells
To further examine the expression of XRN2 and PAPD4 in speciﬁc
neuronal subpopulations, we conducted double-labeling experiments
using anti-parvalbumin (PV), another calcium binding protein. PV is
expressed in a subset of interneurons that innervate distinct domains
of pyramidal cells (Klausberger et al., 2003; Somogyi and Klausberger,
2005), promoting a highly coordinated input integration of these cells.
We detected XRN2 and PAPD4 labeling in PV-positive cells in all regionsfy thepresence of PAPD4 immunolabeling (green) inhippocampal glial cells,we performed
, followed by counter-staining with DAPI (blue). (A) PAPD4 labeling was not observed in
bserved faint PAPD4 labeling in glial cells (blue arrows) as opposed to bright staining in
4 signal to be weaker in GFAP-positive compared with that in GFAP-negative cells in the
he P60 hippocampus (white arrowheads). (G–I) Under high magniﬁcation of the selected
; however, stainingwas strong in GFAP-negative cells (red arrowheads). (J) Quantiﬁcation
ve cells in the P60 hippocampus. Bars represent standard errors of themean. *P b 0.001 in
Fig. 10. XRN2 and PAPD4 are not expressed in endothelial nitric oxide synthase (eNOS)-positive cells. We investigated whether XRN2 (green) is present in endothelial cells by
performing double-labeling experiments using anti-eNOS (red) on sections from the P60 hippocampus, followed by counter-staining with DAPI (blue). (A) In the hilus of the
dentate gyrus (DG), we observed XRN2 labeling to be virtually absent in elongated nuclei of endothelial cells. The pixel intensity proﬁle revealed no overlap among green,
red, and blue signals, indicating the absence of XRN2 labeling from eNOS-positive cells. (B–D) Under high magniﬁcation of the selected area, we observed no accumulation of
XRN2 eNOS-positive cells (white arrow), as opposed to eNOS-negative cells (white arrowheads), which clearly accumulated XRN2. (E) The identiﬁcation of PAPD4 (green) in
endothelial cells (red) was performed using a similar approach. The pixel intensity proﬁle revealed no overlap among green, red and blue channels, indicating that PAPD4 is
virtually absent in endothelial cells. (F–H) Under high magniﬁcation of the selected area, we observed no accumulation of PAPD4 in eNOS-positive cells (white arrows), as
opposed to eNOS-negative cells (white arrowheads), which accumulated PAPD4. Scale bar: 25 μm.
Fig. 11. XRN2 and PAPD4 accumulate in calretinin (CR)-positive cells. (A) To determine which speciﬁc neuronal subpopulations express XRN2 (green), we performed double-
labeling experiments using anti-CR (red) on coronal sections of the P60 hippocampus, followed by counter-staining with DAPI (blue). In a representative image of the CA1 re-
gion, we observed XRN2 staining in CR-positive cells. In the pixel intensity proﬁle, we observed an overlap between the red and green signals, conﬁrming that CR-positive cells
accumulate XRN2. (B–D) Under high magniﬁcation of the selected area, we observed CR-positive (white arrow) and -negative (white arrowheads) cells with similar labeling
intensity. (E) Quantiﬁcation of pixel intensity revealed no difference in the XRN2 signal between CR-positive and -negative cells. (F) We also examined the expression of
PAPD4 (green) in CR-positive cells from the P60 hippocampus. The pixel intensity proﬁle revealed overlap between red and green channels, conﬁrming PAPD4 accumulation
in CR-positive cells. (G–I) In a highly magniﬁed view of the selected area, we observed PAPD4 to be present in CR-positive (red arrow) and CR-negative (red arrowheads)
cells. (J) Quantiﬁcation of pixel intensity revealed similar PAPD4 signals in both CR-positive and -negative cells, although some CR-negative cells exhibited higher labeling
intensity (blue arrowhead). Bars represent standard errors of the mean. Scale bar: 50 μm.
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Fig. 12. XRN2 and PAPD4 are differentially expressed in parvalbumin (PV)-positive cells. (A) To extend the analysis of speciﬁc neuronal subpopulations express XRN2 (green), we
conducted double-labeling experiments using anti-PV (red) on coronal sections of the P60 hippocampus, followed by counter-staining with DAPI (blue). In the representative image of
the CA1 region, we observed XRN2 staining in PV-positive cells. The pixel intensity proﬁle revealed an overlap between green and red signals. (B–D) Under high magniﬁcations of the
selected area, we observed a similar XRN2 staining intensity in PV-positive (white arrow) and -negative cells (white arrowheads). (E) Quantiﬁcation of pixel intensity revealed no signif-
icant difference in XRN2 labeling, indicating similar protein levels in PV-positive and -negative cells. (F) The identiﬁcation of PAPD4 (green) in PV-positive and -negative cells was
performed using a similar approach. Quantiﬁcation of the pixel intensity proﬁle revealed PAPD4 to be present in PV-positive cells, in agreement with the overlay of green and red signals.
(G–I) Under high magniﬁcations of the selected area, we observed PAPD4 accumulation to be higher in PV-positive (red arrow) than in PV-negative (red arrowheads) cells. (J) Quantiﬁ-
cation of pixel intensity conﬁrmed PAPD4 labeling to be higher in PV-positive cells. Bars represent standard errors of the mean. *P b 0.01 in t test. Scale bar: 50 μm.
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ital zooming followed by RGB decomposition data, we indicated that
XRN2 (Figs. 12, A–E) and PAPD4 (Figs. 12, F–J) exhibit a differentialFig. 13. XRN2 and PAPD4 actions on miRNA and miRNA precursors based on the maturation
immature neurons, miRNA biosynthesis follows a well-described process. In the nucleus, pri-m
molecule is translocated into cytosol with the participation of Exportin-5. In the cytosol, pre-mi
miRNAs. One strand is selected for stable association with Argonaute (Ago2), and this strand s
results, PAPD4 is mainly located in the cytoplasmic compartment in immature principal neuro
to the 3′-end of pre-miRNA and miRNA, stabilizing these molecules in the cytoplasm. (C) Repre
neurons than in immature neurons. Thus, XRN2may be involved in the cleavage of miRNA prec
the stabilization of miRNA precursors during development.accumulation in PV-positive cells. Quantiﬁcation of pixel intensities
(n = 3) demonstrated no signiﬁcant differences in XRN2 labeling in
PV-positive and -negative cells (0.97 ± 0.1 vs. 1.13 ± 0.06). However,stage of hippocampal neurons. (A) Representation of an immature pyramidal cell. (B) In
iRNA interacts with Drosha and DGCR8, resulting in its editing to pre-miRNA. This hairpin
RNA is cleaved by DICER and its RNA binding protein TRBP for ﬁnal processing into mature
erves as a guide to target and regulate speciﬁc mRNAs in the RISC complex. Based on our
ns from the hippocampus. Therefore, PAPD4 may be involved in the addition of adenine
sentation of a mature pyramidal cell. (D) XRN2 levels are higher in the nucleus of mature
ursors in differentiated neurons. This results in PAPD4 translocation into the nucleus and in
557E.R. Kinjo et al. / Experimental Neurology 248 (2013) 546–558when the same analysis was performed for PAPD4, we observed a
change in PAPD4 labeling in PV-positive and -negative cells (1.56 ±
0.2 vs. 0.75 ± 0.08, P b 0.01). Taken together, these results revealed ac-
cumulation of PAPD4 in PV-positive interneurons.
Discussion
The control of gene expression in neurons has to be ﬁnely regulated,
considering that these cells operate under a wide variety of conditions.
In the nervous system, control of gene expression by miRNAs has been
investigated in several, distinct, physiological processes (Cao et al.,
2006; Vreugdenhil and Berezikov, 2010). Recent studies have indicated
that the speciﬁcity of these short nucleotide sequences for particular
mRNAs follows a probabilistic, rather than a deterministic approach
(Ragan et al., 2011). Consequently, speciﬁcity of miRNA related-
activity on target genes depends on intracellular concentrations,
which in turn depends on the balance between biosynthesis and degra-
dation (Kai and Pasquinelli, 2010).
In this study, we reported the expression of newly investigated
genes XRN2 and PAPD4 in the hippocampus. XRN2 is involved in the
extinction of miRNA activity rather than in the clearance of inactive
miRNAs (Chatterjee and Grosshans, 2009). In contrast, PAPD4 is a regu-
latory cytoplasmic poly(A) polymerase responsible for the 3′-terminal
adenylation of pre-miRNA and miRNA (Katoh et al., 2009). Based on
our results, XRN2 and PAPD4 accumulate in the same cells, although
regulation of this process is unlikely because of common transcription
factors. This ﬁnding implies that post-transcriptional mechanisms may
control the presence of both proteins. Because the transcript levels of
XRN and PAPD4 are higher and uniform, respectively, during develop-
ment comparedwith the adult,we hypothesize thatmiRNAsmay control
the translational rate of both genes. Regardless of the precisemechanism
underlying this process, we cope with a rare, singular circumstance
in biology: a coincident, almost complete intersected expression of
functionally-opposed genes, reinforcing that their antagonistically
driven actions “make sense” if simultaneously present at the same
cells (Burt and Trivers, 2008; Rowland and Peeper, 2006).
Based on our results, we propose a possible new mechanism that
controls miRNA expression. We are conﬁdent that immature (Figs. 13,
A–B) and mature (Figs. 13, C–D) neurons are the only cell types in the
central nervous system to exhibit such a mechanism, and this conclu-
sion is based on the antagonist-driven actions of XRN2 and PAPD4.
Taking into account the roles attributed to miRNAs in cell differenti-
ation (Andersson et al., 2010; Decembrini et al., 2009;Gao, 2008; Li et al.,
2011; Zheng et al., 2010), it was surprising that both XRN2 and PAPD4
were not expressed by neuronal progenitor cells. In contrast, the pres-
ence of both proteins in the same hippocampal neurons depicts how
gene expression in neuronal function is ﬁnely and speciﬁcally adjusted
depending on the ensuing physiological process. In agreement with
our results, recent studies have demonstrated that translational control
of mRNAs in dendrites is essential for certain types of synaptic plasticity
such as learning and memory (Lee et al., 2012; Udagawa et al., 2012).
Despite this, control of gene expression in speciﬁc cells during physio-
logical conditions remainspuzzling because of the speciﬁc neuronalwir-
ing in the hippocampus. Therefore, regulation of the transcriptome
should be examined on the basis of particular micro-circuitry-related
roles. In this study, we determined that speciﬁc neuronal subtypes,
namely CR- and PV-positive interneurons, differentially accumulate
XRN2 and PAPD4, indicating a unique balance betweenmiRNA degrada-
tion and stabilization in these cells. Considering the roles of CR- and PV-
positive interneurons in inhibitory circuits (Markram et al., 2004;
Zaitsev et al., 2005), it seems feasible that these cells exhibit reﬁned
regulatory mechanisms of the transcriptome in developing and mature
hippocampus. The regulation of synaptic activity has been associated
with fast, promptmechanisms and involves the participation of miRNAs
since neuronal activity rapidly induces the transcription of speciﬁc
miRNAs such as CREB-regulated miRNA-132 (Nudelman et al., 2010).In addition, recent reports describe the critical role of PV-positive inter-
neurons in hippocampal synchrony, spatial representations, and work-
ing memory (Korotkova et al., 2010). In conclusion, it is believed that
XRN2 and PAPD4 are involved in a mechanism that controls miRNA-
related activities in the nervous system.
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